Last reviewed · How we verify
NCT05989555: SCIMITAR
Effects of Radioactive Iodine on the Immune System in Thyroid Cancer
trial testing Blood drawing in Thyroid Carcinoma, Nonmedullary in 30 participants. Status unknown.
1 June 2025
Quick facts
| Lead sponsor | Radboud University Medical Center |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 1 January 2024 |
| Primary completion | 1 June 2025 |
| Estimated completion | 1 December 2025 |
| Sites | 1 location across Netherlands |
Drugs / interventions tested
- Blood drawing
Conditions studied
- Thyroid Carcinoma, Nonmedullary — all drugs for Thyroid Carcinoma, Nonmedullary →
Sponsor
Radboud University Medical Center
Who can join
18 and older, any sex, with Thyroid Carcinoma, Nonmedullary. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Blood will be drawn 1 month before and 2 month after regular radioactive iodine treatment. Monocytes will be isolated. The three main outcomes are whole blood counts, cytokine production upon in vitro stimulation of monocytes and in vitro ROS production by monocytes. These results are compared between patients treated in adjuvant setting and patients treated for persistent structural disease, and between pre- and post-treatment status.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05989555
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Blood drawing
Trials testing the same drug.
- NCT06139042 — Early-stage Detection of LIver, Biliary TRAct and PancReatic Cancers · recruiting
- NCT05667350 — AssesSment of Early-deteCtion basEd oN liquiD Biopsy in Biliary Tract Cancer (ASCEND-BTC) · unknown
- NCT04717219 — Myeloid Cells in Aortic Valve Stenosis · unknown
- NCT04100122 — Luminex-based Assay to Identify Major IgE-binding Episode Among IgE-mediated Wheat-allergic Patient · completed
- NCT03870828 — Clinical Characteristics of Interstitial Pneumonia With Autoimmune Features (IPAF) - a Multicenter Prospective Study · unknown
Other Radboud University Medical Center trials
Trials by the same sponsor.
- NCT07485569 — Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial · Phase 1 · not yet recruiting
- NCT07514325 — MR-guided Adaptive Stereotactic Radiotherapy for Endometrial Cancer · NA · not yet recruiting
- NCT07530263 — Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA) · Phase 1 · not yet recruiting
- NCT07532577 — Intranasal Insulin to Prevent Intensive Care Unit Delirium · Phase 2, PHASE3 · not yet recruiting
- NCT07504172 — Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05989555 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Radboud University Medical Center
- Last refreshed: 18 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05989555.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing